Updated: Aug 22, 2018


As clinical evidence relating to Hypochlorous acid technology continues to emerge as the superior base for advanced tissue therapies so does the scope of application. Leading this growth in clinical application, Te Arai BioFarma recently launched a new Microdacyn + Silicone gel combination product for scar management called Epicyn.


Epicyn is already supported by a recent double-blinded, randomised control trial whereby its efficacy in resolving common scar metrics such as; pliability, height, itch and pain was compared head to head with the current gold standard of topical scar therapy, 100% pure silicone gel (Kelo-Cote). (Gold et al 2017)


The synergistic effects of Microdaycn's HOCl in combination with silicone gel proved to be more effective than standard 100% silicone alone marking the next era in topical silicone scar management regimes, especially post wound healing with non-cytotoxic Microdacyn

Epicyn has a new healthcare professional brochure out now (seen here),

Continue the movement towards hypochlorous acid technology with Epicyn!




More product and clinical information on Epicyn can be found at www.epicyn.com.au or by calling Te Arai BioFarma on 1800 83 2724.




Microdacyn Wound Care solution is now available as a funded item on the Pharmaceutical Benefits Scheme (PBS) for RPBS relevant patients. Currently the RPBS is the only Australian government mechanism to fund wound care related products in the community.


“We are very pleased to have successfully achieved a funded listing in Australia for a certain group of people. The process for the listing was extensive and we look forward to further funding for wound care products in the future” commented Lance Gravatt, Chairman of Te Arai BioFarma.


Wound care and chronic wounds in Australia represent a significant healthcare burden and a significant health budget cost. Groups including Diabetic Foot Australia and the Wounds Australia are working toward securing government funding to improve wound-related outcomes across the population.


Microdacyn is a relatively new technology in Australia which acts to prevent and manage wound infection, reduce inflammation and significantly improve time to wound healing.


The PBS listing of Microdacyn is available here

Clinical details of Microdacyn are available for healthcare professionals here


#healing #superoxidizedsolutions #Microdacyn

The World Health Organisation (WHO) Essential Medicines List (EML) committee considers Microdacyn technology during April 2017. Microdacyn is a super oxidised solution used to prevent and manage infection while clinically provides faster wound healing. The  Essential Medicines List contains carefully selected medicines and medical devices to meet the needs of near 84% of the worlds population, those living in poor, lower or middle income countries.


The EML is also a guide for the funded availability of medicines and medical devices through governments and organisations such as UNICEF.


A successful listing would mean the poor, lower and middle countries would be able to access the same wound care and infection control product Microdacyn, which is currently used in Australia, Europe, New Zealand and the USA.


The WHO is making a significant effort in sourcing non antibiotic technologies to combat the rising issue of drug resistance. WHO 2050 forecasts predict that drug resistance will be the leading case of death worldwide, greater than both cancer and cardiovascular disease.


Full details of the Microdacyn application are available to view here. Currently there is a substantial gap between countries in regard to wound care, for example the International Wound Infection Institute (IWII) 2016 guidelines note hydrogen peroxide products are not recommended, except in low income countries if no other products are available.


With the World Health Organisation (WHO) accepting a Microdacyn application lower income countries will be able to access the same products as the rest of world.


Background on the EML is here http://www.who.int/medicines/services/essmedicines_def/en/

For any queries please contact regulatory@tearaibiofarma.com

  • LinkedIn - Grey Circle
  • Facebook - Grey Circle
  • Instagram - Grey Circle